Menu
No results found.
Weekly Share Price & Valuation Overview
Guard Therapeutics International AB (publ)
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- SEK 457.80M
- Enterprise Value Operating value: market cap + total debt − cash.
- SEK 263.00M
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -9.67
- Shares Outstanding
- 20.17M
- Float Shares
- 9.71M
- Implied Shares Outstanding
- 20.17M
- ROA Return on assets: net income ÷ total assets.
-
-1.05%
- ROE Return on equity: net income ÷ shareholder equity.
-
-2.10%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 4.74
- Total Cash Cash and equivalents.
- SEK 16.10M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- SEK -16.10M
- Revenue per Share (TTM) computed from resolved revenue ÷ shares due to feed inconsistency.
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.